The world’s largest diabetes drug-maker, Novo Nordisk (NYSE:NVO), is reportedly looking to boost its efforts to treat obesity, as the company’s well-established drugs face competition.
At Novo Nordisk’s capital markets day yesterday, CEO Lars Fruergaard Jorgensen told investors that the company wants to rival surgery with their drugs as a solution for obesity.
The drug-maker’s first target – semaglutide.
Get the full story at our sister site, Drug Delivery Business News.
The post Facing pressure in diabetes, Novo Nordisk plans next big push – obesity appeared first on MassDevice.
from MassDevice http://ift.tt/2A4rzQw
Cap comentari:
Publica un comentari a l'entrada